Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05891769
Other study ID # 68169
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date September 27, 2023
Est. completion date July 1, 2027

Study information

Verified date April 2024
Source Stanford University
Contact Andrea Otte, DPT
Phone 650-736-4183
Email anotte@stanford.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date July 1, 2027
Est. primary completion date July 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Suspected parathyroid adenoma (elevated serum calcium and inappropriately normal or high levels of parathyroid hormone) 2. Negative or equivocal 99mTc Sestamibi SPECT/CT 3. Able to provide written consent 4. Total bilirubin = 1.5 x upper limit of normal (ULN) 5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 5 xULN 6. Karnofsky performance status of >50 (or ECOG/WHO equivalent) 7. Women must not be pregnant per the Department of Radiology Policy on Imaging in Potentially Pregnant and Pregnant Women. Exclusion Criteria: 1. Less than 18 years old at the time of radiotracer administration 2. Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 60 mL/min or serum creatinine >1.5 x ULN 3. QTcF >470 msec on electrocardiogram (ECG) or congenital long QT syndrome

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
18Fluorocholine
18F Fluorocholine 5 mCi ± 20% administered intravenously.

Locations

Country Name City State
United States Stanford Hospital and Clinics Stanford California

Sponsors (1)

Lead Sponsor Collaborator
Andrei Iagaru

Country where clinical trial is conducted

United States, 

References & Publications (5)

Ciappuccini R, Morera J, Pascal P, Rame JP, Heutte N, Aide N, Babin E, Reznik Y, Bardet S. Dual-phase 99mTc sestamibi scintigraphy with neck and thorax SPECT/CT in primary hyperparathyroidism: a single-institution experience. Clin Nucl Med. 2012 Mar;37(3):223-8. doi: 10.1097/RLU.0b013e31823362e5. — View Citation

DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med. 2002 Jan;43(1):92-6. Erratum In: J Nucl Med 2002 Apr;43(4):509. — View Citation

Graves CE, Hope TA, Kim J, Pampaloni MH, Kluijfhout W, Seib CD, Gosnell JE, Shen WT, Roman SA, Sosa JA, Duh QY, Suh I. Superior sensitivity of 18F-fluorocholine: PET localization in primary hyperparathyroidism. Surgery. 2022 Jan;171(1):47-54. doi: 10.1016/j.surg.2021.05.056. Epub 2021 Jul 21. — View Citation

Hope TA, Graves CE, Calais J, Ehman EC, Johnson GB, Thompson D, Aslam M, Duh QY, Gosnell JE, Shen WT, Roman SA, Sosa JA, Kluijfhout WP, Seib CD, Villaneuva-Meyer JE, Pampaloni MH, Suh I. Accuracy of 18F-Fluorocholine PET for the Detection of Parathyroid Adenomas: Prospective Single-Center Study. J Nucl Med. 2021 Nov;62(11):1511-1516. doi: 10.2967/jnumed.120.256735. Epub 2021 Mar 5. — View Citation

Kluijfhout WP, Pasternak JD, Gosnell JE, Shen WT, Duh QY, Vriens MR, de Keizer B, Hope TA, Glastonbury CM, Pampaloni MH, Suh I. 18F Fluorocholine PET/MR Imaging in Patients with Primary Hyperparathyroidism and Inconclusive Conventional Imaging: A Prospective Pilot Study. Radiology. 2017 Aug;284(2):460-467. doi: 10.1148/radiol.2016160768. Epub 2017 Jan 25. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of lesions detected by PET/CT for detecting parathyroid adenomas. Inclusion criteria suggest recruiting patients with negative or equivocal SPECT/CT, so based on this there will be 0 lesions on SPECT/CT. The goal is to compare/count the number of lesions from PET/CT, if any present versus no lesions with SPECT/CT up to 1 hour
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04085913 - Exparel Injection Effect on Postoperative Opioid Usage Early Phase 1
Completed NCT04040946 - Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention Phase 3
Completed NCT04344886 - Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery N/A
Completed NCT03469310 - Minimizing Narcotic Analgesics After Endocrine Surgery Phase 4
Not yet recruiting NCT01084356 - Evaluation of a New CZT System N/A
Completed NCT04299425 - Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy N/A
Completed NCT04905641 - The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy
Completed NCT03027557 - Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. Phase 3
Withdrawn NCT03516747 - Preoperational Fine Needle Aspiration of Pathological Parathyroid Gland N/A
Recruiting NCT05152927 - Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy N/A
Completed NCT04570033 - The Utility of 18F-fluorocholine PET/CT in the Imaging of Parathyroid Adenomas N/A
Recruiting NCT05022641 - Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy N/A
Withdrawn NCT02381925 - Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism N/A